EP2504362A1 - Fractions de liaison anti-c5a à activité bloquante élevée - Google Patents

Fractions de liaison anti-c5a à activité bloquante élevée

Info

Publication number
EP2504362A1
EP2504362A1 EP10782561A EP10782561A EP2504362A1 EP 2504362 A1 EP2504362 A1 EP 2504362A1 EP 10782561 A EP10782561 A EP 10782561A EP 10782561 A EP10782561 A EP 10782561A EP 2504362 A1 EP2504362 A1 EP 2504362A1
Authority
EP
European Patent Office
Prior art keywords
seq
amino acid
heavy chain
sequence according
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10782561A
Other languages
German (de)
English (en)
Other versions
EP2504362B1 (fr
Inventor
Renfeng Guo
Niels Christoph Riedemann
Yan Li
Beifen Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InflaRx GmbH
Original Assignee
InflaRx GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2504362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP16199344.9A priority Critical patent/EP3181582B1/fr
Priority to DK16199344.9T priority patent/DK3181582T3/da
Priority to PL10782561T priority patent/PL2504362T3/pl
Priority to EP20153768.5A priority patent/EP3670532A1/fr
Priority to PL16199344T priority patent/PL3181582T3/pl
Priority to EP10782561.4A priority patent/EP2504362B1/fr
Priority to SI201031368A priority patent/SI2504362T1/sl
Application filed by InflaRx GmbH filed Critical InflaRx GmbH
Priority to RS20170025A priority patent/RS55571B1/sr
Publication of EP2504362A1 publication Critical patent/EP2504362A1/fr
Publication of EP2504362B1 publication Critical patent/EP2504362B1/fr
Application granted granted Critical
Priority to HRP20170041TT priority patent/HRP20170041T1/hr
Priority to CY20171100048T priority patent/CY1118463T1/el
Priority to SM201700054T priority patent/SMT201700054B/it
Priority to CY20201100151T priority patent/CY1122674T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a.
  • Preferred binding moieties are anti- C5a antibodies that bind to this conformational epitope.
  • the binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
  • SIRS systemic inflammatory response syndrome
  • C5a is cleaved from C5 upon complement activation.
  • C5a is one of the most potent inflammatory peptides, with a broad spectrum of functions (Guo and Ward 2005).
  • C5a is a glycoprotein present in the blood of healthy humans with a molecular weight of 11.2 kDa.
  • the polypeptide portion of C5a contains 74 amino acids, accounting for a molecular weight of 8.2 kDa while the carbohydrate portion accounts for approximately 3 kDa.
  • C5a exerts its effects through the high-affinity C5a receptors (C5aR and C5L2) (Ward 2009).
  • C5aR belongs to the rhodopsin-type family of G- protein-coupled receptors with seven transmembrane segments; C5L2 is similar but is not G- protein-coupled. It is currently believed that C5a exerts its biological functions primarily through C5a-C5aR interaction, as few biological responses have been found for C5a-C5L2 interaction. C5aR is widely expressed on myeloid cells including neutrophils, eosinophils, basophils, and monocytes, and nonmyeloid cells in many organs, especially in the lung and liver, indicative of the importance of C5a/C5aR signaling. C5a has a variety of biological functions (Guo and Ward 2005).
  • C5a is a strong chemoattractant for neutrophils and also has chemotactic activity for monocytes and macrophages. C5a causes an oxidative burst (0 2 consumption) in neutrophils and enhances phagocytosis and release of granular enzymes. C5a has also been found to be a vasodilator. C5a has been shown to be involved in modulation of cytokine expression from various cell types, to enhance expression of adhesion molecules on neutrophils. It is found that C5a becomes highly detrimental when it is overly produced in the disease settings, as it is a strong inducer and enhancer for inflammatory responses functioning in the up-stream of the inflammatory reaction chain.
  • C5a has been reported to exert numerous pro-inflammatory responses, and has been reported to be harmful during sepsis.
  • Inhibition of C5a or of the C5a receptor (C5aR) by antibodies has been demonstrated to dramatically improve survival in various sepsis models in mice and rats (Czermak et al. 1999; Guo et al. 2000; Huber-Lang et al. 2001b; Riedemann et al. 2002a).
  • C5a acts as an anaphylatoxin and has been reported to exert numerous pro-inflammatory effects.
  • sepsis high levels of C5a have been reported to be associated with significantly worsened outcome in various studies (Bengtson and Heideman 1988; Nakae et al. 1994; Nakae et al. 1996).
  • C5a up-regulates ⁇ 2 integrin expression on neutrophils to promote cell migration into organs (Guo et al. 2002), one of the major causes for multi-organ failure (MOF). It is also found that C5a is attributable to the activation of the coagulation pathway that occurs in the experimental sepsis (Laudes et al. 2002). C5a stimulates the synthesis and release from human leukocytes of pro-inflammatory cytokines such as TNF-a, IL- ⁇ , IL-6, IL-8, and macrophage migration inhibitory factor (MIF) (Hopken et al. 1996; Riedemann et al. 2004a; Strieter et al. 1992).
  • MIF macrophage migration inhibitory factor
  • C5a produces a strong synergistic effect with LPS in production of TNF-a, macrophage inflammatory protein (MEP)-2, cytokine-induced neutrophil chemoattractant (CINC)-l, and IL- ⁇ in alveolar epithelial cells (Riedemann et al. 2002b; Rittirsch et al. 2008). Given that complement activation is an event occurring during the onset of sepsis, C5a may come into play before emergence of the "inflammatory cytokine storm". It appears that C5a plays a key role in orchestrating the performance of the cytokine network and the formation of systemic inflammatory response syndrome (SIRS).
  • SIRS systemic inflammatory response syndrome
  • Blockade of C5a in the setting of experimental sepsis dramatically attenuates MOF and SIRS.
  • Widespread up-regulation of C5aR expression occurs during onset of sepsis, and blockade of C5a/C5aR interaction by anti-C5a, or anti-C5aR antibodies, or C5aR antagonists renders highly protective effects in rodent models of sepsis (Czermak et al. 1999; Huber-Lang et al. 2001b; Riedemann et al. 2002a).
  • blockade of C5a has also been proven to be protective in many other models of inflammation such as ischemia/reperfusion injury, renal disease, graft rejection, malaria, rheumatoid arthritis, infectious bowel disease, inflammatory lung disease, lupus-like auto-immune diseases, neurodegenerative disease, etc. in various species as partially reviewed under Klos A. et al (Klos et al. 2009) and Allegretti M. et al (Allegretti et al. 2005). Moreover, it has been recently discovered that blockade of C5a has shown a strong therapeutic benefit in a tumor model in mice (Markiewski et al. 2008).
  • Antibodies that specifically bind to the C5a part but not to the C5b part of C5 are known from the prior art (Klos et al. (1998) J. Immunol. Meth. I l l: 241-252; WO 01/15731; WO 03/015819).
  • anti-C5a antibodies exhibited only moderate blocking activities on biological effects induced by C5a.
  • anti-C5a antibodies of the prior art were either not capable of achieving a complete blockade of C5a-induced biological effects or had to be used in superstoichiometric amounts to reach a reasonably high blockage of C5a activity.
  • anti-C5a antibodies or other binding moieties displaying a stronger blocking activity for C5a-induced biological effects while specifically binding to C5a with high affinity.
  • preferably such antibodies should not bind to C5b and consequently should not affect the biological activities of C5b.
  • the inventors of the present invention were able to identify a new conformational binding epitope with corresponding binding antibodies that fulfil the above mentioned advanced requirements and others.
  • two anti-C5a antibodies out more than 2000 could be generated that exhibit an unprecedented blocking activity to C5a-induced biological effects when employed in stoichiometric amounts, i.e. 0.5 mole of a bivalent antibody per mole of C5a.
  • the present invention relates to a binding moiety which binds to a conformational epitope formed by amino acid sequences X 1 X 2 ETCEX 3 RX 4 (SEQ ID NO: 18) and X 5 X6KX 7 X 8 X 9 L (SEQ ID NO: 19) of C5a, wherein X] is selected from the group consisting of N, H, D, F, K, Y, and T; X 2 is selected from the group consisting of D, L, Y, and H; X 3 is selected from the group consisting of Q, E, and K; X4 is selected from the group consisting of A, V, and L; X 5 is selected from the group consisting of S, H, P, and N; X 6 is selected from the group consisting of H and N; X 7 is selected from the group consisting of D, N, H, P, and G; X 8 is selected from the group consisting of M, L, I, and V; and X9 is selected
  • the present invention relates to an antibody of an antigen-binding fragment thereof comprising: (i) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 6; or (ii) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 7; wherein the heavy chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1 , 2, or 3 amino acid additions.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising (a) the binding moiety according to the first aspect or (b) the antibody or antigen-binding fragment thereof according to the second aspect and further comprising one or more pharmaceutically acceptable carriers, diluents, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents, and/or preservatives.
  • the present invention relates to a use of (a) a binding moiety according to the first aspect or (b) an antibody or antigen-binding fragment thereof according to the second aspect for the preparation of a pharmaceutical composition for the prevention and or treatment of various diseases involving acute inflammation such as systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, ischemia/reperfusion related injuries such as ischemic heart disease, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft versus host reactions, but also diseases involving a chronic type of inflammation such as renal glomerular diseases such as glomerulonephritis and other entities of renal failure, rheumatoid arthritis and similar auto-immune diseases such as Bechterew's disease, lupus-type diseases, inflammatory bowel disease, Crohn's disease, tumor growth, or solid organ cancer.
  • SIRS systemic inflammatory response syndrome
  • sepsis severe sepsis
  • septic shock isch
  • the present invention is directed to a method of treating systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, ischemia/reperfusion related injuries such as ischemic heart disease, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft versus host reactions, renal glomerular diseases such as glomerulonephritis and other entities of renal failure, rheumatoid arthritis and similar auto-immune diseases such as Bechterew's disease, lupus- type diseases, inflammatory bowel disease, Crohn's disease, tumor growth, or solid organ cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of (a) a binding moiety according to the first aspect or (b) an antibody or antigen-binding fragment thereof according to the second aspect.
  • SIRS systemic inflammatory response syndrome
  • the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, H.G.W, Nagel, B. and Kolbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).
  • human C5a refers to the following 74 amino acid peptide: TLQKKIEEIA AKYKHSWKK CCYDGACVNN DETCEQRAAR ISLGPRCIKA FTECCWASQ LRANISHKDM QLGR (SEQ ID NO: 1).
  • binding moiety refers to any molecule or part of a molecule that can specifically bind to a target molecule or target epitope.
  • Preferred binding moieties in the context of the present application are (a) antibodies or antigen-binding fragments thereof; (b) oligonucleotides; (c) antibody-like proteins; or (d) peptidomimetics.
  • Binding moieties that can be used for practicing the present invention are capable of binding to a conformational epitope of mammalian C5a which is formed by the two amino acid sequences X,X2ETCEX 3 RX 4 (SEQ ID NO: 18) and X 5 X 6 KX 7 X 8 X 9 L (SEQ ID NO: 19), wherein X ⁇ is selected from the group consisting of N, H, D, F, K, Y, and T; X 2 is selected from the group consisting of D, L, Y, and H; X 3 is selected from the group consisting of Q, E, and K; X 4 is selected from the group consisting of A, V, and L; X 5 is selected from the group consisting of S, H, P, and N; X6 is selected from the group consisting of H and N; X 7 is selected from the group consisting of D, N, H, P, and G; X 8 is selected from the group consisting of M, L, I,
  • Binding moieties that are particularly suitable for practicing the present invention are capable of binding to a conformational epitope of human C5a which is formed by the two amino acid sequences NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3).
  • a first compound e.g. an antibody
  • a second compound e.g. an antigen, such as a target protein
  • a dissociation constant 3 ⁇ 4 to said second compound of 1 mM or less, preferably 100 ⁇ or less, preferably 50 ⁇ or less, preferably 30 ⁇ or less, preferably 20 ⁇ or less, preferably 10 ⁇ or less, preferably 5 ⁇ or less, more preferably 1 ⁇ or less, more preferably 900 nM or less, more preferably 800 nM or less, more preferably 700 nM or less, more preferably 600 nM or less, more preferably 500 nM or less, more preferably 400 nM or less, more preferably 300 nM or less, more preferably 200 nM or less, even more preferably 100 nM or less, even more preferably 90 nM or less, even more preferably 80 nM or less, even more preferably 70 nM or less, even more preferably
  • binding preferably relates to a specific binding.
  • Specific binding means that a binding moiety (e.g. an antibody) binds stronger to a target such as an epitope for which it is specific compared to the binding to another target.
  • a binding moiety binds stronger to a first target compared to a second target if it binds to the first target with a dissociation constant (3 ⁇ 4) which is lower than the dissociation constant for the second target.
  • the dissociation constant (3 ⁇ 4) for the target to which the binding moiety binds specifically is more than 10-fold, preferably more than 20-fold, more preferably more than 50-fold, even more preferably more than 100-fold, 200-fold, 500-fold or 1000-fold lower than the dissociation constant (3 ⁇ 4) for the target to which the binding moiety does not bind specifically.
  • the term (measured in "mol/L”, sometimes abbreviated as “M") is intended to refer to the dissociation equilibrium constant of the particular interaction between a binding moiety (e.g. an antibody or fragment thereof) and a target molecule (e.g. an antigen or epitope thereof).
  • a binding moiety e.g. an antibody or fragment thereof
  • a target molecule e.g. an antigen or epitope thereof.
  • an “epitope”, also known as antigenic determinant, is the part of a macromolecule that is recognized by the immune system, specifically by antibodies, B cells, or T cells.
  • an “epitope” is the part of a macromolecule capable of binding to a binding moiety (e.g. an antibody or antigen-binding fragment thereof) as described herein.
  • binding preferably relates to a specific binding.
  • Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.
  • a “conformational epitope” refers to an epitope of a linear macromolecule (e.g. a polypeptide) that is formed by the three-dimensional structure of said macromolecule.
  • a “conformational epitope” is a “discontinuous epitope", i.e. the conformational epitope on the macromolecule (e.g. a polypeptide) which is formed from at least two separate regions in the primary sequence of the macromolecule (e.g. the amino acid sequence of a polypeptide).
  • an epitope is considered to be a "conformational epitope" in the context of the present invention, if the epitope consists of at least two separate regions in the primary sequence to which a binding moiety of the invention (e.g. an antibody or an antigen-binding fragment thereof) binds simultaneously, wherein these at least two separate regions are interrupted by one more regions in the primary sequence to which a binding moiety of the invention does not bind.
  • a binding moiety of the invention e.g. an antibody or an antigen-binding fragment thereof
  • an antibody or an antigen-binding fragment thereof binds, wherein these at least two separate amino acid sequences are interrupted by one more amino acid sequences in the primary sequence to which a binding moiety of the invention does not bind.
  • the interrupting amino acid sequence is a contiguous amino acid sequence comprising two or more amino acids to which the binding moiety does not bind.
  • the at least two separate amino acid sequences to which a binding moiety of the invention binds are not particularly limited with regard to their length. Such a separate amino acid sequence may consists of only one amino acid as long as the total number of amino acids within said at least two separate amino acid sequences is sufficiently large to effect specific binding between the binding moiety and the conformational epitope.
  • a “paratope” is the part of an antibody that recognizes the epitope.
  • a “paratope” is the part of a binding moiety (e.g. an antibody or antigen-binding fragment thereof) as described herein that recognizes the epitope.
  • antibody typically refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, or an antigen-binding portion thereof.
  • antibody also includes all recombinant forms of antibodies, in particular of the antibodies described herein, e.g. antibodies expressed in prokaryotes, unglycosylated antibodies, and any antigen-binding antibody fragments and derivatives as described below.
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH or V H ) and a heavy chain constant region.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as VL or VL) and a light chain constant region.
  • VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
  • antigen-binding fragment of an antibody (or simply “binding portion”), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
  • binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) Fab fragments, monovalent fragments consisting of the VL, VH, CL and CH domains; (ii) F(ab') 2 fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragments consisting of the VH and CH domains; (iv) Fv fragments consisting of the VL and VH domains of a single arm of an antibody, (v) dAb fragments (Ward et al., (1989) Nature 341: 544-546), which consist of a VH domain; (vi) isolated complementarity determining regions (CDR), and (vii) combinations of two or more isolated CDRs which may optionally be joined by a synthetic linker.
  • Fab fragments monovalent fragments consisting of the VL, VH, CL and CH domains
  • F(ab') 2 fragments bivalent fragments compris
  • the two domains of the Fv fragment, VL and VH are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883).
  • single chain Fv single chain Fv
  • Such single chain antibodies are also intended to be encompassed within the term "antigen-binding fragment" of an antibody.
  • a further example is a binding-domain immunoglobulin fusion protein comprising (i) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, (ii) an immunoglobulin heavy chain CH2 constant region fused to the hinge region, and (iii) an immunoglobulin heavy chain CH3 constant region fused to the CH2 constant region.
  • the binding domain polypeptide can be a heavy chain variable region or a light chain variable region.
  • the binding-domain immunoglobulin fusion proteins are further disclosed in US 2003/0118592 and US 2003/0133939. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.
  • antigen- binding fragments are so-called microantibodies, which are derived from single CDRs.
  • microantibodies which are derived from single CDRs.
  • Heap et al., 2005 describe a 17 amino acid residue microantibody derived from the heavy chain CDR3 of an antibody directed against the gpl20 envelope glycoprotein of HIV- 1.
  • Other examples include small antibody mimetics comprising two or more CDR regions that are fused to each other, preferably by cognate framework regions.
  • Such a small antibody mimetic comprising V H CDRl and V L CDR3 linked by the cognate V H FR2 has been described by Qiu et al., 2007.
  • antibody or antigen-binding fragment thereof refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain an antigen-binding site that immunospecifically binds an antigen. Also comprised are immunoglobulin-like proteins that are selected through techniques including, for example, phage display to specifically bind to a target molecule or target epitope, e.g.
  • X 1 X 2 ETCEX 3 RX 4 SEQ ID NO: 18
  • X 5 X 6 KX 7 X 8 X 9 L SEQ ID NO: 19
  • X is selected from the group consisting of N, H, D, F, K, Y, and T
  • X 2 is selected from the group consisting of D, L, Y, and H
  • X 3 is selected from the group consisting of Q, E, and K
  • X4 is selected from the group consisting of A, V, and L
  • X 5 is selected from the group consisting of S, H, P, and N
  • Xe is selected from the group consisting of H and N
  • X 7 is selected from the group consisting of D, N, H, P, and G
  • X 8 is selected from the group consisting of M, L, I, and V
  • X9 is selected from the group consisting of Q, L, and I; or to the conformational epitop
  • the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl, IgG2, preferably IgG2a and IgG2b, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.
  • type e.g., IgG, IgE, IgM, IgD, IgA and IgY
  • class e.g., IgGl, IgG2, preferably IgG2a and IgG2b, IgG3, IgG4, IgAl and IgA2
  • subclass of immunoglobulin molecule e.g., IgG, IgE, IgM, IgD, IgA and IgY
  • subclass of immunoglobulin molecule e.g., IgG, IgE, IgM, Ig
  • Antibodies and antigen-binding fragments thereof usable in the invention may be from any animal origin including birds and mammals.
  • the antibodies or fragments are from human, chimpanzee, rodent (e.g. mouse, rat, guinea pig, or rabbit), chicken, turkey, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog origin. It is particularly preferred that the antibodies are of human or murine origin.
  • Antibodies of the invention also include chimeric molecules in which an antibody constant region derived from one species, preferably human, is combined with the antigen binding site derived from another species, e.g. mouse.
  • antibodies of the invention include humanized molecules in which the antigen binding sites of an antibody derived from a non-human species (e.g. from mouse) are combined with constant and framework regions of human origin.
  • antibodies of the invention can be obtained directly from hybridomas which express the antibody, or can be cloned and recombinantly expressed in a host cell (e.g., a CHO cell, or a lymphocytic cell).
  • a host cell e.g., a CHO cell, or a lymphocytic cell.
  • host cells are microorganisms, such as E. coli, and fungi, such as yeast.
  • they can be produced recombinantly in a transgenic non-human animal or plant.
  • chimeric antibody refers to those antibodies wherein one portion of each of the amino acid sequences of heavy and light chains is homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular class, while the remaining segment of the chain is homologous to corresponding sequences in another species or class.
  • the variable region of both light and heavy chains mimics the variable regions of antibodies derived from one species of mammals, while the constant portions are homologous to sequences of antibodies derived from another.
  • One clear advantage to such chimeric forms is that the variable region can conveniently be derived from presently known sources using readily available B-cells or hybridomas from non-human host organisms in combination with constant regions derived from, for example, human cell preparations.
  • variable region has the advantage of ease of preparation and the specificity is not affected by the source, the constant region being human is less likely to elicit an immune response from a human subject when the antibodies are injected than would the constant region from a non-human source.
  • definition is not limited to this particular example.
  • humanized antibody refers to a molecule having an antigen binding site that is substantially derived from an immunoglobulin from a non-human species, wherein the remaining immunoglobulin structure of the molecule is based upon the structure and/or sequence of a human immunoglobulin.
  • the antigen binding site may either comprise complete variable domains fused onto constant domains or only the complementarity determining regions (CDR) grafted onto appropriate framework regions in the variable domains.
  • Antigen-binding sites may be wild-type or modified by one or more amino acid substitutions, e.g. modified to resemble human immunoglobulins more closely.
  • Some forms of humanized antibodies preserve all CDR sequences (for example a humanized mouse antibody which contains all six CDRs from the mouse antibody). Other forms have one or more CDRs which are altered with respect to the original antibody.
  • a CDR grafting protocol typically comprises three decision-making points: (1) definition of regions determining the specificity of the donor antibody, i.e. the target for grafting, (2) identification of a source of human sequences to be utilized as FR donors, and (3) selection of residues outside of the region defining the specificity, i.e. determining amino acid positions that are targets for back mutation to restore or improve the affinity of the humanized antibody.
  • the experimental structure of the non-human antibody in complex with the antigen provides a detailed map of residues in contact with the antigen and therefore those responsible for determining its specificity.
  • the structural information can be complemented with alanine scanning mutagenesis and/or combinatorial mutagenesis to identify the residues contributing most to the binding energy or to the functional paratope. Since the functional paratope is a subset of the residues in contact, grafting only the functional paratope would reduce the number of non-human residues in the humanized product. However, only in rare cases are the experimental structure of the antigen-antibody complex and/or the functional paratope available at the beginning of a humanization protocol.
  • CDRs are often employed as regions defining the specificity. It is also possible to use a combination of CDR and HV loop as targets for grafting. To reduce the number of residues to be grafted on the human FRs, SDR grafting has been described, i.e. the grafting of specificity-determining residues (SDRs).
  • the second step in a typical CDR grafting protocol is to identify human FR donors.
  • Initial works utilized FRs of human antibodies of known structure, regardless of their homology to the non-human antibody. This approach is known as “Fixed FR method”. Later works used human sequences having the highest homology to the non-human antibody. This approach has been termed “Best Fit”. While “best fit” strategies tend to result in antibodies with higher affinity, other parameters such as low immunogenicity and production yields have to be taken into account, too, when choosing an FR for humanization. Thus, combinations of "best fit” and "fixed FR” are also possible. For example, the V L part can be humanized according to the fixed FR method and the V H part can be humanized according to the best fit method, or vice versa.
  • the third step in a typical CDR grafting protocol is to define mutations that would restore or prevent affintiy losses.
  • Back mutations have to be carefully designed based on the structure or a model of the humanized antibody and tested experimentally.
  • a web site for automated antibody modeling called WAM can be found at the URL http://antibody.bath.ac.uk.
  • Software for protein structure modeling can be downloaded at the sites http://salilab.org/modeller/modeller.html (Modeller) and http://spdbv.vital-it.ch (Swiss Pdb Viewer).
  • Resurfacing is similar to CDR grafting and shares the first two decision-making points. In contrast to CDR grafting, resurfacing retains the non-exposed residues of the non- human antibody. Only surface residues in the non-human antibody are changed to human residues.
  • CDR grafting relies on the FR comparison between the non-human and the humans sequences
  • superhumanization is based on a CDR comparison so that FR homology is irrelevant.
  • the approach includes a comparison of the non-human sequence with the functional human germline gene repertoire. Those genes encoding the same or closely related canonical structures to the murine sequences are then selected. Next, within the genes sharing the canonical structures with the non-human antibody, those with highest homology within the CDRs are chosen as FR donors. Finally, the non-human CDRs are grafted onto these FRs.
  • HSC Human String Content
  • FR library approach a collection of residue variants are introduced at specific positions in the FR followed by panning of the library to select the FR that best supports the grafted CDR.
  • this approach resembles CDR grafting but instead of creating a few back mutations in the FR, a combinatorial library of typically more than 100 mutational variants is constructed.
  • This approach includes combining the V H or V L domain of a given non-human antibody specific for a particular antigen with a human V H and V L library. Subsequently, specific human V domains are selected against the antigen of interest.
  • a non- human antibody can be humanized by first combining the non-human V H with a library of human light chains. The library is then selected against the target antigen by phage display and the selected V L is cloned into a library of human V H chains and selected against the target antigen. It is also possible to start with combining the non-human V L with a library of human heavy chains.
  • the library is then selected against the target antigen by phage display and the selected V H is cloned into a library of human V L chains and selected against the target antigen.
  • a fully human antibody with similar affinity as the non-human antibody can be isolated.
  • inhibition ELISA which allows for the selection of clones recognizing the same epitope as the parent antibody.
  • CDR retention can be applied to avoid an epitope drift. In CDR retention, one or more non-human CDRs are retained, preferably the heavy chain CDR3, since this CDR is at the center of the antigen binding site.
  • FR shuffling In the FR shuffling approach, whole FRs are combined with the non-human CDRs. Using FR shuffling, Dall'Acqua and co-workers humanized a murine antibody. All six CDRs of the murine antibody were cloned into a library containing all human germline gene FRs (Dall'Acqua et al., 2005). The libraries were screened for binding in a two-step selection process, first humanizing V L , followed by V H . In a later study, a one-step FR shuffling process was successfully used (Damschroder et al., 2007).
  • Oligonucleotide sequences encoding all known human germline light chain ( ⁇ ) frameworks are disclosed in Dall'Acqua et al., 2005, as Appendix A. Oligonucleotide sequences encoding all known human germline heavy chain frameworks are disclosed in Dall'Acqua et al., 2005, as Appendix B.
  • Humaneering allows for isolation of antibodies that are 91-96% homologous to human germline gene antibodies.
  • the method is based on experimental identification of essential minimum specificity determinants (MSDs) and on sequential replacement of non-human fragments into libraries of human FRs and assessment of binding. It begins with regions of the CDR3 of non-human VH and VL chains and progressively replaces other regions of the non- human antibody into the human FRs, including the CDR1 and CDR2 of both VH and V L .
  • Some of the aforementioned humanization methods can be performed without information about the FR sequences in the donor antibody, namely the "Fixed FR Method" (a variant of CDR-grafting), Superhumanization, Framework-shuffling, and Humaneering. Variations of the "fixed FR method" were successfully carried out by Qin et al., 2007 and Chang et al., 2007.
  • Qin et al. constructed an antibody fragment comprising a human heavy chain variable region in which the three CDR regions were replaced by antigenic peptides, which were derived from the CDR sequences of a murine antibody.
  • Chang et al. continued these experiments and constructed an scFv fragment, in which all CDRs from the VH part and CDR3 from the VL part were replaced by antigenic peptides, which were derived from the CDR sequences of a murine antibody.
  • human antibodies include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • Human antibodies of the invention include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described for example in U.S. Patent No. 5,939,598 by Kucherlapati & Jakobovits.
  • the term "monoclonal antibody” as used herein refers to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody displays a single binding specificity and affinity for a particular epitope.
  • the monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a non-human animal, e.g. mouse, fused to an immortalized cell.
  • recombinant antibody includes all antibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal with respect to the immunoglobulin genes or a hybridoma prepared therefrom, (b) antibodies isolated from a host cell transformed to express the antibody, e.g. from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of immunoglobulin gene sequences to other DNA sequences.
  • transfectoma includes recombinant eukaryotic host cells expressing an antibody, such as CHO cells, NS/0 cells, HEK293 cells, HEK293T cells, plant cells, or fungi, including yeast cells.
  • a heterologous antibody is defined in relation to a transgenic organism producing such an antibody. This term refers to an antibody having an amino acid sequence or an encoding nucleic acid sequence corresponding to that found in an organism not consisting of the transgenic organism, and being generally derived from a species other than the transgenic organism.
  • heterohybrid antibody refers to an antibody having light and heavy chains of different organismal origins.
  • an antibody having a human heavy chain associated with a murine light chain is a heterohybrid antibody.
  • antibodies and antigen-binding fragments thereof suitable for use in the present invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific, recombinant, heterologous, heterohybrid, chimeric, humanized (in particular CDR-grafted), deimmunized, or human antibodies, Fab fragments, Fab' fragments, F(ab') 2 fragments, fragments produced by a Fab expression library, Fd, Fv, disulfide-linked Fvs (dsFv), single chain antibodies (e.g. scFv), diabodies or tetrabodies (Holliger P. et al. (1993) Proc. Natl.
  • nanobodies also known as single domain antibodies
  • anti-idiotypic antibodies including, e.g., anti-Id antibodies to antibodies of the invention
  • epitope-binding fragments of any of the above include, e.g., anti-Id antibodies to antibodies of the invention, and epitope-binding fragments of any of the above.
  • the antibodies described herein are preferably isolated.
  • An "isolated antibody” as used herein is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to C5a is substantially free of antibodies that specifically bind antigens other than C5a).
  • An isolated antibody that specifically binds to an epitope, isoform or variant of human C5a may, however, have cross-reactivity to other related antigens, e.g. from other species (e.g. C5a species homologs, such as rat C5a).
  • an isolated antibody may be substantially free of other cellular material and/or chemicals.
  • a combination of "isolated" monoclonal antibodies relates to antibodies having different specificities and being combined in a well defined composition.
  • naturally occurring refers to the fact that an object can be found in nature.
  • a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally occurring.
  • nucleic acid aptamer refers to a nucleic acid molecule that has been engineered through repeated rounds of in vitro selection or SELEX (systematic evolution of ligands by exponential enrichment) to bind to a target molecule (for a review see: Brody E.N. and Gold L. (2000), Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74(1):5-13).
  • the nucleic acid aptamer may be a DNA or RNA molecule.
  • the aptamers may contain modifications, e.g. modified nucleotides such as 2'-fluorine-substituted pyrimidines.
  • antibody-like protein refers to a protein that has been engineered (e.g. by mutagenesis of loops) to specifically bind to a target molecule.
  • an antibody-like protein comprises at least one variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the antibody-like protein to levels comparable to that of an antibody.
  • the length of the variable peptide loop typically consists of 10 to 20 amino acids.
  • the scaffold protein may be any protein having good solubility properties.
  • the scaffold protein is a small globular protein.
  • Antibody-like proteins include without limitation affibodies, anticalins, and designed ankyrin repeat proteins (for review see: Binz H.K.
  • Antibody-like proteins can be derived from large libraries of mutants, e.g. be panned from large phage display libraries and can be isolated in analogy to regular antibodies. Also, antibody-like binding proteins can be obtained by combinatorial mutagenesis of surface- exposed residues in globular proteins. Antibody-like proteins are sometimes referred to as "peptide aptamers".
  • a "peptidomimetic" is a small protein-like chain designed to mimic a peptide.
  • Peptidomimetics typically arise from modification of an existing peptide in order to alter the molecule's properties. For example, they may arise from modifications to change the molecule's stability or biological activity. This can have a role in the development of drug-like compounds from existing peptides. These modifications involve changes to the peptide that will not occur naturally (such as altered backbones and the incorporation of nonnatural amino acids).
  • Constant substitutions may be made, for instance, on the basis of similarity in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the amino acid residues involved.
  • Amino acids can be grouped into the following six standard amino acid groups:
  • conservative substitutions are defined as exchanges of an amino acid by another amino acid listed within the same group of the six standard amino acid groups shown above. For example, the exchange of Asp by Glu retains one negative charge in the so modified polypeptide.
  • glycine and proline may be substituted for one another based on their ability to disrupt a-helices.
  • Some preferred conservative substitutions within the above six groups are exchanges within the following sub-groups: (i) Ala, Val, Leu and He; (ii) Ser and Thr; (ii) Asn and Gin; (iv) Lys and Arg; and (v) Tyr and Phe. Given the known genetic code, and recombinant and synthetic DNA techniques, the skilled scientist readily can construct DNAs encoding the conservative amino acid variants.
  • non-conservative substitutions or “non-conservative amino acid exchanges” are defined as exchanges of an amino acid by another amino acid listed in a different group of the six standard amino acid groups (1) to (6) shown above.
  • inhibitory activity e.g. enzyme inhibitory activity
  • activating activity e.g. enzyme- activating activity
  • toxic effects e.g., it is not required that the variant or derivative exhibits such an activity to the same extent as the parent polypeptide.
  • a variant is regarded as a variant within the context of the present application, if it exhibits the relevant activity to a degree of at least 10% of the activity of the parent polypeptide.
  • a derivative is regarded as a derivative within the context of the present application, if it exhibits the relevant biological activity to a degree of at least 10% of the activity of the parent polypeptide.
  • the relevant "biological activity" in the context of the present invention is a binding activity to a conformational epitope of C5a formed by amino acid sequences (SEQ ID NO: 18) and X 5 X 6 KX 7 X 8 X 9 L (SEQ ID NO: 19), wherein is selected from the group consisting of N, H, D, F, K, Y, and T; X 2 is selected from the group consisting of D, L, Y, and H; X 3 is selected from the group consisting of Q, E, and K; XJ, is selected from the group consisting of A, V, and L; X 5 is selected from the group consisting of S, H, P, and N; X 6 is selected from the group consisting of H and N; X 7 is selected from the group consisting of D, N, H,
  • a particularly relevant "biological activity" in the context of the present invention is a binding activity to the conformational epitope of human C5a formed by the amino acid sequences according to SEQ ID NO: 2 and SEQ ID NO: 3.
  • the relevant "biological activity” in the context of the present invention is a binding activity to the conformational epitope of human C5a formed by the amino acid sequences DETCEQR (SEQ ID NO: 4) and KDM.
  • Assays for determining binding activity are known to a person of ordinary skill in the art and include ELISAs such as the one described in the Examples section.
  • a "patient” means any mammal or bird who may benefit from a treatment with the target-binding moiety described herein.
  • a “patient” is selected from the group consisting of laboratory animals (e.g. mouse or rat), domestic animals (including .e.g. guinea pig, rabbit, chicken, turkey, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog), or primates including chimpanzees and human beings. It is particularly preferred that the "patient” is a human being.
  • SIRS Systemic inflammatory response syndrome
  • Heart rate 100 beats per minute (tachycardia).
  • Respiratory rate 20 breaths per minute or, on blood gas, a P a C0 2 less than 32 mm Hg (4.3 kPa) (tachypnea or hypocapnia due to hyperventilation).
  • Sepsis Defined as SIRS in response to a confirmed infectious process. Infection can be suspected or proven (by culture, stain, or polymerase chain reaction (PCR)), or a clinical syndrome pathognomonic for infection. Specific evidence for infection includes WBCs in normally sterile fluid (such as urine or cerebrospinal fluid (CSF), evidence of a perforated viscus (free air on abdominal x-ray or CT scan, signs of acute peritonitis), abnormal chest x- ray (CXR) consistent with pneumonia (with focal opacification), or petechiae, purpura, or purpura fulminans
  • Severe sepsis Defined as sepsis with organ dysfunction, hypoperfusion, or hypotension.
  • Septic shock Defined as sepsis with refractory arterial hypotension or hypoperfusion abnormalities in spite of adequate fluid resuscitation. Signs of systemic hypoperfusion may be either end-organ dysfunction or serum lactate greater than 4 mmol/dL. Other signs include oliguria and altered mental status. Patients are defined as having septic shock if they have sepsis plus hypotension after aggressive fluid resuscitation (typically upwards of 6 liters or 40 ml/kg of crystalloid).
  • tumor an abnormal group of cells or tissue that grows by a rapid, uncontrolled cellular proliferation and continues to grow after the stimuli that initiated the new growth cease. Tumors show partial or complete lack of structural organization and functional coordination with the normal tissue, and usually form a distinct mass of tissue, which may be either benign or malignant.
  • metastasis is meant the spread of cancer cells from its original site to another part of the body.
  • the formation of metastasis is a very complex process and depends on detachment of malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the endothelial basement membranes to enter the body cavity and vessels, and then, after being transported by the blood, infiltration of target organs. Finally, the growth of a new tumor at the target site depends on angiogenesis. Tumor metastasis often occurs even after the removal of the primary tumor because tumor cells or components may remain and develop metastatic potential.
  • the term "metastasis” according to the invention relates to "distant metastasis" which relates to a metastasis which is remote from the primary tumor and the regional lymph node system.
  • treat means accomplishing one or more of the following: (a) reducing the severity and/or duration of the disorder; (b) limiting or preventing development of symptoms characteristic of the disorder(s) being treated; (c) inhibiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting or preventing recurrence of the disorder(s) in patients that have previously had the disorder(s); and (e) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for the disorder(s).
  • prevent means preventing that a disorder occurs in subject.
  • administering includes in vivo administration, as well as administration directly to tissue ex vivo, such as vein grafts.
  • an “effective amount” is an amount of a therapeutic agent sufficient to achieve the intended purpose.
  • the effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration.
  • the effective amount in each individual case may be determined empirically by a skilled artisan according to established methods in the art.
  • “Pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic agent is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as saline solutions in water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • a saline solution is a preferred carrier when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • the compounds of the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
  • suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.
  • Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
  • the formulation should suit the mode of administration.
  • the present invention is directed to a binding moiety which binds to a conformational epitope formed by amino acid sequences XiX 2 ETCEX 3 RX 4 (SEQ ID NO: 18) and X 5 X 6 KX 7 X 8 X9L (SEQ ID NO: 19) of C5a, wherein Xi is selected from the group consisting of N, H, D, F, K, Y, and T; X 2 is selected from the group consisting of D, L, Y, and H; X 3 is selected from the group consisting of Q, E, and K; X4 is selected from the group consisting of A, V, and L; X 5 is selected from the group consisting of S, H, P, and N; X 6 is selected from the group consisting of H and N; X 7 is selected from the group consisting of D, N, H, P, and G; X 8 is selected from the group consisting of M, L, I, and V; and X9 is selected from
  • SEQ ID NO: 18 is a consensus sequence determined by comparing amino acids 30-38 of human C5a with the corresponding amino acid sequences in Pan troglodytes, Macaca mulatto, Sus scrofa, Equus caballus, Bos Taurus, Mus musculus, Rattus norvegicus, Canis lupus, and Monodelphis domestica.
  • SEQ ID NO: 19 is a consensus sequence determined by comparing amino acids 66-72 of human C5a with the corresponding amino acid sequences in Pan troglodytes, Macaca mulatto, Sus scrofa, Equus caballus, Bos Taurus, Mus musculus, Rattus norvegicus, Canis lupus, and Monodelphis domestica.
  • the binding moiety binds to at least one amino acid of the amino acid sequence X 2 ETCEX 3 R (SEQ ED NO: 20), wherein X 2 and X 3 are defined as above.
  • SEQ ID NO: 20 is a shorter version of the consensus sequence according to SEQ ID NO: 18 and corresponds to amino acids 31-37 of human C5a.
  • the binding moiety binds to at least one amino acid of the amino acid sequence X 6 KX 7 X 8 Xg (SEQ ED NO: 21), preferably KX 7 X 8> wherein X 6 , X 7 , X 8 , and X9 are defined as above.
  • SEQ ID NO: 21 is a shorter version of the consensus sequence according to SEQ ID NO: 19 and corresponds to amino acids 67-71 of human C5a.
  • KX 7 X 8 is a shorter version of the consensus sequence according to SEQ ED NO: 21 and corresponds to amino acids 68-70 of human C5a.
  • the binding moiety binds at the same time to at least one amino acid within the amino acid sequence X 2 ETCEX 3 R (SEQ ID NO: 20) and to at least one amino acid within the amino acid sequence KX 7 X 8 , wherein X 2 , X 3 , X 7 , and X are defined as above.
  • the conformational epitope is formed by (a) amino acid sequences NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of C5a (sequences from Homo sapiens and Pan troglodytes); (b) amino acid sequences HDETCEQRA (SEQ ID NO: 22) and SHKDLQL (SEQ ID NO: 23) of C5a (sequences from Macaca mulatta); (c) amino acid sequences DDETCEERA (SEQ ID NO: 24) and SHKNIQL (SEQ ID NO: 25) of C5a (sequences from Sus scrofa); (d) amino acid sequences DLETCEQRA (SEQ ID NO: 26) and SH HIQL (SEQ ID NO: 27) of C5a (sequences from Equus caballus); (e) amino acid sequences DDETCEQRA (SEQ ED NO: 28) and HHKNM
  • the binding moiety binds to at least one amino acid of an amino acid sequence selected from the group consisting of (a) DETCEQR (SEQ ID NO: 4); (b) DETCEER (SEQ ID NO: 38); (c) LETCEQR (SEQ ID NO: 39); (e) YETCEER (SEQ ID NO: 40); (f) YETCEQR (SEQ ID NO: 41); and (g) HETCEKR (SEQ ID NO: 42).
  • the binding moiety binds to at least one amino acid of an amino acid sequence selected from the group consisting of (a) HKDMQ (SEQ ID NO: 5), preferably KDM; (b) HKDLQ (SEQ ID NO: 43), preferably KDL; (c) HKNIQ (SEQ ID NO: 44), preferably K ; (d) HKHIQ (SEQ ID NO: 45), preferably KHI; (e) HKNMQ (SEQ ID NO: 46), preferably KNM; (f) HKPVQ (SEQ ID NO: 47), preferably KPV; (g) HKGML (SEQ ID NO: 48), preferably KGM; (h) NKPLQ (SEQ ID NO: 49), preferably KPL; and (i) HKPVI (SEQ ID NO: 50), preferably KPV.
  • HKDMQ SEQ ID NO: 5
  • KDM HKDLQ
  • SEQ ID NO: 43 preferably KDL
  • HKNIQ SEQ ID NO: 44
  • the C5a is human C5a.
  • the binding moiety binds to a conformational epitope formed by amino acids NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of human C5a.
  • a binding moiety according to this preferred embodiment of the first aspect binds at the same time to at least one amino acid within the amino acid sequence according to SEQ ID NO: 2 and to at least one amino acid within the amino acid sequence according to SEQ ID NO: 3.
  • SEQ ID NO: 2 corresponds to amino acids 30-38 of human C5a.
  • SEQ ID NO: 3 corresponds to amino acids 66-72 of human C5a.
  • the amino acid sequence of human C5a is depicted in SEQ ID NO: 1.
  • the binding moiety binds to at least one of amino acids DETCEQR (SEQ ID NO: 4).
  • SEQ ID NO: 4 corresponds to amino acids 31-37 of human C5a.
  • the binding moiety binds to at least one of amino acids HKDMQ (SEQ ID NO: 5), more preferably to at least one of amino acids KDM.
  • SEQ ID NO: 5 correspond to amino acids 67-71 of human C5a; the sequence KDM corresponds to amino acids 68-70 of human C5a.
  • the binding moiety binds at the same time to at least one amino acid within the amino acid sequence DETCEQR (SEQ ID NO: 4) and to at least one amino acid within the amino acid sequence KDM.
  • the two sequences forming the conformational epitope are separated by 1-50 contiguous amino acids that do not participate in binding to the binding moiety of the invention.
  • such amino acids that do not participate in binding to the binding moiety of the invention will be referred to as "non- binding amino acids”.
  • the two sequences forming the conformational epitope are preferably separated by 6-45 contiguous non-binding amino acids, more preferably by 12-40 contiguous non-binding amino acids, more preferably by 18-35 contiguous non-binding amino acids, more preferably by 24-30 contiguous non-binding amino acids, more preferably by 25-29 contiguous non-binding amino acids, even more preferably by 26-28 contiguous non-binding amino acids, and most preferably by 27 contiguous non-binding amino acids.
  • the binding moiety has a binding constant to C5a, preferably human C5a, with a 3 ⁇ 4 value of 10 nM or less, preferably 9 nM or less, more preferably 8 nM or less, more preferably 7 nM or less, more preferably 6 nM or less, more preferably 5 nM or less, more preferably 4 nM or less, more preferably 3 nM or less, more preferably 2 nM or less, and even more preferably 1 nM or less.
  • one binding moiety exhibits at least 75% blocking activity, preferably at least 80% blocking activity, more preferably at least 85% blocking activity, more preferably at least 90% blocking activity, more preferably at least 95% blocking activity for biological effects induced by one molecule C5a, preferably human C5a.
  • These preferred blocking activities refer to those embodiments, wherein the binding moiety comprises a single paratope binding to C5a, preferably human C5a.
  • the binding moiety according to the first aspect exhibits at least 75% blocking activity, preferably at least 80% blocking activity, more preferably at least 85% blocking activity, more preferably at least 90% blocking activity, and more preferably at least 95% blocking activity for biological effects induced by C5a.
  • a preferred biological effect to be blocked is C5a-induced lysozyme release from human whole blood cells. Assays for determining this C5a-induced lysozyme release and its blocking are described in the examples section.
  • the binding moiety does not inhibit CH50 activity in human plasma.
  • Assays for determining CH50 activity are known to the skilled person and are described below in the examples section.
  • the binding moiety does not exhibit a blocking activity on at least one C5b induced biological effect, preferably the binding moiety does not exhibit a blocking activity on any C5b induced biological effect.
  • the binding moiety is capable of reducing E. coli induced IL-8 production in human whole blood.
  • Assays for measuring IL-8 production in whole blood are known to the skilled person and will be described below in the examples section.
  • the binding moiety is selected from: (a) antibodies or antigen-binding fragments thereof; (b) oligonucleotides; (c) antibody-like proteins; or (d) peptidomimetics.
  • the binding moiety is an antibody or an antigen-binding fragment thereof, said antibody being selected from the group consisting of polyclonal antibodies, monoclonal antibodies, monovalent antibodies, bispecific antibodies, heteroconjugate antibodies, multispecific antibodies, deimmunized antibodies, chimeric antibodies, humanized (in particular CDR-grafted) antibodies, and human antibodies, .
  • the binding moiety is an antigen-binding fragment of an antibody, said fragment being selected from the group consisting of Fab fragments, Fab' fragments, F(ab') 2 fragments, Fd fragments, Fv fragments, disulfide-linked Fvs (dsFv), single domain antibodies (also known as nanobodies), and single chain Fv (scFv) antibodies.
  • the binding moiety is an antibody or an antigen-binding fragment thereof comprising, (i) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 6; or (ii) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 7; wherein the heavy chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.
  • the antibody or fragment thereof further comprises: (i) a light chain CDR3 sequence as set forth in SEQ ID NO: 8; or (ii) a light chain CDR3 sequence as set forth in SEQ ID NO: 9; wherein the light chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.
  • the antibody or fragment further comprises at least one of the following sequences: (i) a heavy chain CDR2 sequence according to SEQ ID NO: 10; (ii) a heavy chain CDR2 sequence according to SEQ ID NO: 11; (iii) a light chain CDR2 sequence according to SEQ ID NO: 12; (iv) a light chain CDR2 sequence according to SEQ ID NO: 13; (v) a heavy chain CDR1 sequence according to SEQ ID NO: 14; (vi) a heavy chain CDR1 sequence according to SEQ ID NO: 15; (vii) a light chain CDR1 sequence according to SEQ ID NO: 16; or (viii) a light chain CDR1 sequence according to SEQ ID NO: 17; wherein the heavy chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; wherein the light chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges,
  • the binding moiety is an oligonucleotide.
  • the oligonucleotide is a nucleic acid aptamer, such as a DNA aptamer or RNA aptamer or a mixed aptamer comprising DNA and RNA nucleotides.
  • one or more nucleotides may be replaced by modified nucleotides such as 2 '-fluorine-substituted pyrimidines.
  • Nucleic acid aptamers may also be conjugated with fluorescent reporter molecules, affinity tags and/or macromolecules. For example, conjugating the aptamer to polyethylenglycol (PEG) or to a comparable macromolecule will increase the biological half-life of the aptamer.
  • PEG polyethylenglycol
  • the binding moiety is an antibody-like protein, e.g. an antibody-like protein as exemplified above in the "Definitions" section.
  • the binding moiety is a peptidomimetic.
  • Peptidomimetics suitable for practicing the present invention are preferably based on antibody-like proteins as described above.
  • a preferred embodiment of the first aspect is directed to the binding moiety for the prevention and or treatment of various disease involving acute inflammation such as systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, ischemia/reperfusion related injuries such as ischemic heart disease, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft versus host reactions, but also diseases involving chronic types of inflammation such as renal glomerular diseases such as glomerulonephritis and other entities of renal failure, rheumatoid arthritis and similar auto-immune diseases such as Bechterew's disease, lupus-type diseases, inflammatory bowel disease, Crohn's disease, tumor growth, or solid organ cancer.
  • SIRS systemic inflammatory response syndrome
  • sepsis sepsis
  • severe sepsis severe sepsis
  • septic shock ischemia/reperfusion related injuries
  • ischemia/reperfusion related injuries such as ischemic heart disease, acute
  • the present invention is directed to an antibody or an antigen- binding fragment thereof comprising: (i) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 6; or (ii) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 7; wherein the heavy chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.
  • the total number of these optional changes in the amino acid sequence of SEQ ID NO: 6, i.e. the total number of exchanges, deletions and additions is 1 or 2.
  • the total number of these optional changes in the amino acid sequence of SEQ ID NO: 7, i.e. the total number of exchanges, deletions and additions is 1 or 2.
  • the antibody or antigen-binding fragment thereof further comprises: (i) a light chain CDR3 sequence as set forth in SEQ ID NO: 8; or (ii) a light chain CDR3 sequence as set forth in SEQ ID NO: 9; wherein the light chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.
  • the total number of these optional changes in the amino acid sequence of SEQ ID NO: 8, i.e. the total number of exchanges, deletions and additions is 1 or 2.
  • the total number of these optional changes in the amino acid sequence of SEQ ID NO: 9, i.e. the total number of exchanges, deletions and additions is 1 or 2.
  • the second aspect of the present invention also refers to an antibody or an antigen- binding fragment thereof comprising: (i) a light chain CDR3 sequence as set forth in SEQ ID NO: 8; or (ii) a light chain CDR.3 sequence as set forth in SEQ ID NO: 9; wherein the light chain CDR3 sequence optionally comprises 1 , 2 or 3 amino acid exchanges, 1 , 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.
  • the total number of these optional changes in the amino acid sequence of SEQ ID NO: 8, i.e. the total number of exchanges, deletions and additions is 1 or 2.
  • the total number of these optional changes in the amino acid sequence of SEQ ID NO: 9, i.e. the total number of exchanges, deletions and additions is l or 2.
  • the antibody or antigen-binding fragment thereof further comprises at least one of the following sequences: (i) a heavy chain CDR2 sequence according to SEQ ID NO: 10; (ii) a heavy chain CDR2 sequence according to SEQ ID NO: 11; (iii) a light chain CDR2 sequence according to SEQ ID NO: 12; (iv) a light chain CDR2 sequence according to SEQ ID NO: 13; (v) a heavy chain CDRl sequence according to SEQ ID NO: 14; (vi) a heavy chain CDRl sequence according to SEQ ID NO: 15; (vii) a light chain CDRl sequence according to SEQ ID NO: 16; or (viii) a light chain CDRl sequence according to SEQ ID NO: 17; wherein the heavy chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; wherein the light chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid
  • the total number of these optional changes in each one of the amino acid sequences according to SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17, i.e. the total number of exchanges, deletions and additions in each sequence, is 1 or 2.
  • the antibody is selected from the group consisting of polyclonal antibodies, monoclonal antibodies, monovalent antibodies, bispecific antibodies, heteroconjugate antibodies, multispecific antibodies, deimmunized antibodies, chimeric antibodies, humanized (in particular CDR-grafted) antibodies, and human antibodies.
  • the antigen-binding fragment of an antibody is selected from the group consisting of Fab fragments, Fab' fragments, F(ab') 2 fragments, Fd fragments, Fv fragments, disulfide-linked Fvs (dsFv), single domain antibodies (also known as nanobodies), and single chain Fv (scFv) antibodies.
  • the antibody or antigen-binding fragment thereof binds to a conformational epitope formed by amino acid sequences X 1 X 2 ETCEX 3 RX 4 (SEQ ID NO: 18) and X 5 X6KX 7 X 8 X 9 L (SEQ ID NO: 19) of C5a, wherein Xi is selected from the group consisting of N, H, D, F, , Y, and T; X is selected from the group consisting of D, L, Y, and H; X 3 is selected from the group consisting of Q, E, and K; X4 is selected from the group consisting of A, V, and L; X 5 is selected from the group consisting of S, H, P, and N; X 6 is selected from the group consisting of H and N; X 7 is selected from the group consisting of D, N, H, P, and G; X 8 is selected from the group consisting of M, L, I, and V; and X 9 is
  • an antibody or antigen-binding fragment according to the second aspect binds at the same time to at least one amino acid within the amino acid sequence according to SEQ ID NO: 18 and to at least one amino acid within the amino acid sequence according to SEQ ID NO: 19.
  • the antibody or antigen-binding fragment thereof binds to at least one amino acid of the amino acid sequence X 2 ETCEX 3 R (SEQ ID NO: 20), wherein X 2 and X 3 are defined as above.
  • the antibody or antigen-binding fragment thereof binds to at least one amino acid of the amino acid sequence X 6 KX 7 X 8 X 9 (SEQ ID NO: 21), more preferably KX 7 X 8j wherein X 6 , X 7 , X 8 , and X 9 are defined as above.
  • the antibody or antigen-binding fragment thereof binds at the same time to at least one amino acid within the amino acid sequence X 2 ETCEX 3 R (SEQ ID NO: 20) and to at least one amino acid within the amino acid sequence KX 7 X 8 , wherein X 2 , X 3 , X 7 , and X 8 are defined as above.
  • the conformational epitope is formed by (a) amino acid sequences NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of C5a (sequences from Homo sapiens and Pan troglodytes); (b) amino acid sequences HDETCEQRA (SEQ ID NO: 22) and SHKDLQL (SEQ ID NO: 23) of C5a (sequences from Macaca mulatta); (c) amino acid sequences DDETCEERA (SEQ ID NO: 24) and SHKNIQL (SEQ ID NO: 25) of C5a (sequences from Sus scrofa); (d) amino acid sequences DLETCEQRA (SEQ ID NO: 26) and SHKHIQL (SEQ ID NO: 27) of C5a (sequences from Equus caballus); (e) amino acid sequences DDETCEQRA (SEQ ID NO: 28) and HHKNM
  • the antibody or antigen-binding fragment thereof binds to at least one amino acid within an amino acid sequence selected from the group consisting of (a) DETCEQR (SEQ ID NO: 4); (b) DETCEER (SEQ ID NO: 38); (c) LETCEQR (SEQ ID NO: 39); (e) YETCEER (SEQ ID NO: 40); (f) YETCEQR (SEQ ID NO: 41); and (g) HETCEKR (SEQ ID NO: 42).
  • the antibody or antigen-binding fragment thereof binds to at least one amino acid within an amino acid sequence selected from the group consisting of (a) HKDMQ (SEQ ID NO: 5), preferably KDM; (b) HKDLQ (SEQ ID NO: 43), preferably KDL; (c) HKNIQ (SEQ ID NO: 44), preferably KNI; (d) HKHIQ (SEQ ID NO: 45), preferably KHI; (e) HKNMQ (SEQ ID NO: 46), preferably KNM; (f) HKPVQ (SEQ ID NO: 47), preferably KPV; (g) HKGML (SEQ ID NO: 48), preferably KGM; (h) NKPLQ (SEQ ID NO: 49), preferably KPL; and (i) HKPVI (SEQ ID NO: 50), preferably KPV.
  • HKDMQ SEQ ID NO: 5
  • KDM HKDLQ
  • SEQ ID NO: 43 preferably KDL
  • HKNIQ SEQ
  • the C5a is human C5a.
  • the antibody or antigen-binding fragment thereof binds to a conformational epitope formed by amino acids NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of human C5a.
  • an antibody or antigen-binding fragment thereof according to this preferred embodiment of the second aspect binds at the same time to at least one amino acid within the amino acid sequence according to SEQ ID NO: 2 and to at least one amino acid within the amino acid sequence according to SEQ ID NO: 3.
  • the antibody or antigen-binding fragment thereof binds to at least one amino acid within the amino acid sequence DETCEQR (SEQ ID NO: 4). In more preferred embodiments of the second aspect, the antibody or antigen-binding fragment thereof binds to at least one amino acid within the amino acid sequence HKDMQ (SEQ ID NO: 5), more preferably to at least one amino acid within the amino acid sequence KDM. In particularly preferred embodiments, the antibody or antigen- binding fragment thereof binds at the same time to at least one amino acid within the amino acid sequence DETCEQR (SEQ ID NO: 4) and to at least one amino acid within the amino acid sequence KDM.
  • the antibody or antigen-binding fragment thereof has a binding constant to C5a, preferably human C5a, with a 3 ⁇ 4 value of 10 nM or less, preferably 9 nM or less, more preferably 8 nM or less, more preferably 7 nM or less, more preferably 6 nM or less, more preferably 5 nM or less, more preferably 4 nM or less, more preferably 3 nM or less, more preferably 2 nM or less, and even more preferably 1 nM or less.
  • one antibody or antigen-binding fragment thereof exhibits at least 75% blocking activity, preferably at least 80% blocking activity, more preferably at least 85% blocking activity, more preferably at least 90% blocking activity, more preferably at least 95% blocking activity for biological effects induced by one molecule C5a, preferably human C5a.
  • These preferred blocking activities refer to those embodiments, wherein the antibody (or the antigen-binding fragment thereof) comprises a single paratope binding to C5a, preferably human C5a.
  • the antibody (or the antigen-binding fragment thereof) comprises two or more C5a-specific paratopes, said blocking activities of at least 75%, preferably at least 80%, more preferably at least 85%, etc.
  • a typical anti-C5a antibody of the IgG-type comprises two paratopes capable of binding to C5a
  • a typical anti-C5a antibody of the IgM-type comprises ten paratopes capable of binding to C5a.
  • blocking activity of an antibody of the IgG-type should be determined by contacting said antibody with C5a in a molar ratio of 1 :2.
  • Blocking activity of an antibody of the IgM-type should be determined by contacting said antibody with C5a in a molar ratio of 1 :10.
  • the paratopes within the antibody and C5a are present in equimolar concentrations.
  • the antibody or antigen- binding fragment thereof exhibits at least 75% blocking activity, preferably at least 80% blocking activity, more preferably at least 85% blocking activity, more preferably at least 90% blocking activity, and more preferably at least 95% blocking activity for biological effects induced by C5a.
  • a preferred biological effect to be blocked is C5a-induced lysozyme release from human whole blood cells. Assays for determining this C5a-induced lysozyme release and its blocking are described in the examples section.
  • the antibody or antigen-binding fragment thereof does not inhibit CH50 activity in human plasma.
  • Assays for determining CH50 activity are known to the skilled person and are described below in the examples section.
  • the antibody or antigen-binding fragment thereof does not exhibit a blocking activity on at least one C5b induced biological effect, preferably the antibody or antigen-binding fragment thereof does not exhibit a blocking activity on any C5b induced biological effect.
  • the antibody or antigen-binding fragment thereof is capable of reducing E. coli induced IL-8 production in human whole blood.
  • Assays for measuring IL-8 production in whole blood are known to the skilled person and will be described below in the examples section.
  • a preferred embodiment of the second aspect is directed to the antibody or antigen- binding fragment thereof for the prevention and or treatment of various diseases involving acute inflammation such as systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, ischemia/reperfusion related injuries such as ischemic heart disease, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft versus host reactions, but also diseases involving chronic types of inflammation such as renal glomerular diseases such as glomerulonephritis and other entities of renal failure, rheumatoid arthritis and similar auto-immune diseases such as Bechterew's disease, lupus-type diseases, inflammatory bowel disease, Crohn's disease, tumor growth, or solid organ cancer.
  • SIRS systemic inflammatory response syndrome
  • sepsis sepsis
  • severe sepsis severe sepsis
  • septic shock ischemia/reperfusion related injuries
  • ischemia/reperfusion related injuries such as ische
  • the antibody or antigen- binding fragment thereof comprises one of the sets of heavy chain CDR3, heavy chain CDR2, and heavy chain CDR1 sequences as listed below in Table 1, wherein each heavy chain CDR3 sequence optionally comprises 1 , 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; wherein each heavy chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; and wherein each heavy chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions: Table 1: Sets of heavy chain CDR sequences suitable for use in the antibodies or fragments thereof of the present invention
  • the antibody or antigen- binding fragment thereof comprises one of the following sets of light chain CDR3, light chain CDR2, and light chain CDR1 sequences as listed in Table 2, wherein each light chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; wherein each light chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; and wherein each light chain CDR1 sequence optionally comprises 1 , 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1 , 2, or 3 amino acid additions: Table 2: Sets of light chain CDR sequences suitable for use in the antibodies or fragments thereof of the present invention
  • the antibody or antigen-binding fragment thereof comprises one of the heavy CDR sets A-H listed above in Table 1 and one of the light chain CDR sets I-IV listed above in Table 2, i.e. one of the following combinations of sets: A-I, A-II, A-III, A-IV, B-I, B-II, B-III, B-IV, C-I, C-II, C-III, C-IV, D-I, D-II, D-III, D-rV, E-I, E-II, E-III, E-IV, F-I, F-II, F-III, F-IV, G-I, G-II, G-III, G-IV, H-I, Fill, H-III, or H-IV, wherein each heavy chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, preferably conservative amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; wherein each heavy chain CDR3 sequence optionally comprises 1, 2
  • the antibody or antigen- binding fragment thereof comprises a VH domain that comprises, essentially consists of or consists of (i) the VH domain of INab308 or (ii) the VH domain of INab708.
  • FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 sequences defining the VH domains of INab308 and INab708 are shown below in Table 4.
  • the antibody or antigen- binding fragment thereof comprises a VL domain that comprises, essentially consists of or consists of (i) the VL domain of INab308 or (ii) the VL domain of INab708.
  • FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 sequences defining the VL domains of INab308 and INab708 are shown below in Table 4.
  • the antibody or antigen-binding fragment thereof comprises a VH domain and a VL domain, wherein
  • said VH domain comprises, essentially consists of or consists of the VH domain of INab308 and said VL domain comprises, essentially consists of or consists of the VL domain of INab308; or
  • said VH domain comprises, essentially consists of or consists of the VH domain of INab708 and said VL domain comprises, essentially consists of or consists of the VL domain of INab708.
  • the antibody or antigen- binding fragment thereof comprising one or more CDRs, a set of CDRs or a combination of sets of CDRs as described herein comprises said CDRs in a human antibody framework.
  • Reference herein to an antibody comprising with respect to the heavy chain thereof a particular chain, or a particular region or sequence preferably relates to the situation wherein all heavy chains of said antibody comprise said particular chain, region or sequence. This applies correspondingly to the light chain of an antibody.
  • a sequence modified with respect to a specific sequence when it replaces the specific sequence in an antibody retains binding of said antibody to C5a, in particular to the conformational epitope of C5a identified herein, and preferably retains functions of said antibody as described herein, e.g. blocking C5a-induced lysozyme release from human whole blood cells and/or reducing E. coli induced IL-8 production in human whole blood.
  • CDR regions will be either identical or highly homologous to the regions specified herein.
  • highly homologous it is contemplated that from 1 to 5, preferably from 1 to 4, such as 1 to 3 or 1 or 2 substitutions, deletions, or additions may be made in the CDRs.
  • the hypervariable and variable regions may be modified so that they show substantial homology with the regions specifically disclosed herein.
  • amino acid sequences described herein in particular those of human heavy chain constant regions to adapt the sequence to a desired allotype, e.g. an allotype found in the Caucasian population.
  • the present invention further comprises antibodies in which alterations have been made in the Fc region in order to change the functional or pharmacokinetic properties of the antibodies. Such alterations may result in a decrease or increase of Clq binding and CDC or of FcyR binding and ADCC. Substitutions can, for example, be made in one or more of the amino acid residues of the heavy chain constant region, thereby causing an alteration in an effector function while retaining the ability to bind to the antigen as compared with the modified antibody, cf. U.S. Pat. No. 5,624,821 and U.S. Pat. No. 5,648,260.
  • the in vivo half-life of antibodies can be improved by modifying the salvage receptor epitope of the Ig constant domain or an Ig-like constant domain such that the molecule does not comprise an intact CH2 domain or an intact Ig Fc region, cf. U.S. Pat. No. 6,121,022 and U.S. Pat. No. 6,194,551.
  • the in vivo half-life can furthermore be increased by making mutations in the Fc region, e.g., by substituting threonine for leucine at position 252, by substituting threonine for serine at position 254, or by substituting threonine for phenylalanine at position 256, cf. U.S. Pat. No. 6,277,375.
  • the glycosylation pattern of antibodies can be modified in order to change the effector function of the antibodies.
  • the antibodies can be expressed in a transfectoma which does not add the fucose unit normally attached to Asn at position 297 of the Fc region in order to enhance the affinity of the Fc region for Fc-Receptors which, in turn, will result in an increased ADCC of the antibodies in the presence of NK cells, cf. Shield et al. (2002) JBC, 277: 26733.
  • modification of galactosylation can be made in order to modify CDC.
  • mutations can be introduced randomly along all or part of an anti-C5a antibody coding sequence, such as by saturation mutagenesis, and the resulting modified anti-C5a antibodies can be screened for binding activity.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising (a) the binding moiety according to the first aspect or (b) the antibody or antigen-binding fragment thereof according to the second aspect, and further comprising one or more pharmaceutically acceptable carriers, diluents, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents, and/or preservatives.
  • the present invention is directed to a use of (a) a binding moiety according to the first aspect or (b) an antibody or antigen-binding fragment thereof according to the second aspect, for the preparation of a pharmaceutical composition for the prevention and or treatment of various diseases involving acute inflammation such as systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, ischemia/reperfusion related injuries such as ischemic heart disease, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft versus host reactions, but also diseases involving chronic types of inflammation such as renal glomerular diseases such as glomerulonephritis and other entities of renal failure, rheumatoid arthritis and similar auto-immune diseases such as Bechterew's disease, lupus-type diseases, inflammatory bowel disease, Crohn's disease, tumor growth, or solid organ cancer.
  • SIRS systemic inflammatory response syndrome
  • sepsis severe sepsis
  • septic shock ischemia
  • the present invention is directed to a method of preventing and or treating various diseases involving acute inflammation such as systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, ischemia/reperfusion related injuries such as ischemic heart disease, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft versus host reactions, but also diseases involving chronic types of inflammation such as renal glomerular diseases such as glomerulonephritis and other entities of renal failure, rheumatoid arthritis and similar auto-immune diseases such as Bechterew's disease, lupus-type diseases, inflammatory bowel disease, Crohn's disease, tumor growth, or solid organ cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of (a) a binding moiety according to the first aspect or (b) an antibody or antigen-binding fragment thereof according to the second aspect.
  • SIRS systemic inflammatory response syndrome
  • sepsis sepsis
  • a pharmaceutical composition as described above or a binding moiety may be administered to a patient by any route established in the art which provides a sufficient level of the binding moiety in the patient. It can be administered systemically or locally. Such administration may be parenterally, transmucosally, e.g., orally, nasally, rectally, intravaginally, sublingually, submucosally, transdermally, or by inhalation. Preferably, administration is parenteral, e.g., via intravenous or intraperitoneal injection, and also including, but is not limited to, intra-arterial, intramuscular, intradermal and subcutaneous administration. If the pharmaceutical composition of the present invention is administered locally it can be injected directly into the organ or tissue to be treated, e.g. into the organ afflicted by a tumour.
  • a binding moiety e.g. an antibody or antigen-binding fragment thereof
  • compositions adapted for oral administration may be provided as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions.
  • Tablets or hard gelatine capsules may comprise lactose, starch or derivatives thereof, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, stearic acid or salts thereof.
  • Soft gelatine capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. Solutions and syrups may comprise water, polyols and sugars.
  • An active agent intended for oral administration may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used).
  • a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
  • a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
  • glyceryl monostearate or glyceryl distearate may be used.
  • compositions adapted for transdermal administration may be provided as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • Pharmaceutical compositions adapted for topical administration may be provided as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • a topical ointment or cream is preferably used.
  • the active ingredient may be employed with either a paraffinic or a water- miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water base or a water-in-oil base.
  • compositions adapted for topical administration to the eye include eye drops.
  • the active ingredient can be dissolved or suspended in a suitable carrier, e.g., in an aqueous solvent.
  • Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouthwashes.
  • compositions adapted for nasal administration may comprise solid carriers such as powders (preferably having a particle size in the range of 20 to 500 microns). Powders can be administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nose from a container of powder held close to the nose.
  • compositions adopted for nasal administration may comprise liquid carriers, e.g., nasal sprays or nasal drops. These compositions may comprise aqueous or oil solutions of the active ingredient.
  • Compositions for administration by inhalation may be supplied in specially adapted devices including, but not limited to, pressurized aerosols, nebulizers or insufflators, which can be constructed so as to provide predetermined dosages of the active ingredient.
  • pharmaceutical compositions of the invention are administered via the nasal cavity to the lungs.
  • compositions adapted for rectal administration may be provided as suppositories or enemas.
  • Pharmaceutical compositions adapted for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injectable solutions or suspensions, which may contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially isotonic with the blood of an intended recipient.
  • Other components that may be present in such compositions include water, alcohols, polyols, glycerine and vegetable oils, for example.
  • Compositions adapted for parenteral administration may be presented in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, e.g., sterile saline solution for injections, immediately prior to use.
  • a sterile liquid carrier e.g., sterile saline solution for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically-sealed container such as an ampule or sachette indicating the quantity of active agent.
  • composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampule of sterile saline can be provided so that the ingredients may be mixed prior to administration.
  • an inhibitor of chemoattraction can be delivered in a controlled-release system.
  • the inhibitor may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
  • a pump may be used (see Sefton (1987) CRC Crit. Ref. Biomed. Eng. 14: 201; Buchwald et al. (1980) Surgery 88:507; Saudek et al. (1989) N. Eng. J. Med. 321: 574).
  • the compound in another embodiment, can be delivered in a vesicle, in particular a liposome (see Langer (1990) Science 249:1527-1533; Treat et al. (1989) in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez -Berestein and Fidler (eds.), Liss, N.Y., 353-365; WO 91/04014; U.S. 4,704,355).
  • a liposome see Langer (1990) Science 249:1527-1533; Treat et al. (1989) in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez -Berestein and Fidler (eds.), Liss, N.Y., 353-365; WO 91/04014; U.S. 4,704,355).
  • polymeric materials can be used (see Medical Applications of Controlled Release (1974) Langer and Wise (eds.), CRC Press: Boca Raton, Fla.; Controlled Drug Bioavailability, Drug Product Design and Performance, (1984) Smolen and Ball (eds.), Wiley: N.Y.; Ranger and Peppas (1953) J. Macromol. Sci. Rev. Macromol. Chem. 23: 61 ; see also Levy et al. (1985) Science 228:190; During et al. (1989) Ann. Neurol. 25: 351; Howard et al. (1989) J. Neurosurg. 71: 105).
  • a controlled release system can be placed in proximity of the therapeutic target, i.e., the target cells, tissue or organ, thus requiring only a fraction of the systemic dose (see, e.g., Goodson (1984) 115-138 in Medical Applications of Controlled Release, vol. 2).
  • Other controlled release systems are discussed in the review by Langer ( ⁇ 990, Science 249: 1527-1533).
  • compositions of the invention may be desirable to administer locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as silastic membranes, or fibers.
  • the preferred effective dose will be determined by a skilled artisan based upon considering several factors which will be known to one of ordinary skill in the art. Such factors include the particular form of the pharmaceutical composition, e.g. polypeptide or vector, and its pharmacokinetic parameters such as bioavailability, metabolism, half-life, etc., which will have been established during the usual development procedures typically employed in obtaining regulatory approval for a pharmaceutical compound. Further factors in considering the dose include the condition or disease to be prevented and or treated or the benefit to be achieved in a normal individual, the body mass of the patient, the route of administration, whether administration is acute or chronic, concomitant medications, and other factors well known to affect the efficacy of administered pharmaceutical agents. Thus the precise dosage should be decided according to the judgment of the practitioner and each patient's circumstances, e.g., depending upon the condition and the immune status of the individual patient, according to standard clinical techniques.
  • the subject being administered the binding moiety or antibody of the invention is additionally treated with a chemotherapeutic agent, radiation, or an agent that modulates, e.g., enhances or inhibits, the expression or activity of an Fc receptor, e.g. an Fc-gamma receptor, such as a cytokine.
  • a chemotherapeutic agent e.g. an Fc-gamma receptor
  • Typical cytokines for administration during treatment include granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon- ⁇ (IFN- ⁇ ), and tumor necrosis factor (TNF).
  • Typical therapeutic agents include, among others, antineoplastic agents such as doxorubicin, cisplatin, taxotere, 5-fluoruracil, methotrexat, gemzitabin and cyclophosphamide.
  • Fig. 1 shows the effect of C5a mutants on enzyme releases from blood cells
  • Potential amino acids in C5a molecules for constitution of antibody epitopes were mutated into alanine, and these C5a mutants were tested for their bioactivity to induce lysozyme releases from human whole blood cells.
  • C5a site mutation resulting in more than 50% bioactivity loss in comparison to human C5a was considered as a critical site for C5a biological function. These sites are 24, 29, 31, 37, 68, and 69.
  • Fig. 2 shows the binding capability of INab308 to C5a mutants
  • Fig. 3 shows the binding capability of INab708 to C5a mutants
  • Human plasma hemolytic activity was determined by classical CH50 assay. Mabs to human C5a including INab708, INab308, and F20, were pre-incubated with human plasma, and then CH50 assay was performed subsequently. Among these antibodies, F20 strongly inhibits CH50 activity, while INab708 and I ab308 have no influence when used at a concentration of approx. 5 ⁇ , which is significantly higher than the C5 concentration occurring in human whole blood (approx. 0.4 ⁇ ).
  • Fig. 5 shows a comparison of the blocking effects of INab308, INab708, and L2B23 on C5a bioactivity
  • Blocking activity of I ab308, I ab708 and L2B23 was assessed by C5a-induced lysozyme release assay.
  • the molar ratio of antibody to C5a was set to 1 : 2 to evaluate the blocking activity of one antibody to two C5a molecules-elicited biological effect.
  • the data show that INab308 and INab708 possess very high blocking activity (>90%) to C5a bioactivity, while L2B23 only shows a minimal effect.
  • Fig. 6 shows the inhibitory effect of INab308 and INab708 on ⁇ .co/t-induced IL-8 production in human whole blood
  • E. coli was incubated with whole blood for 4 hours, and IL-8 levels were assessed by ELISA. In the presence of INab308 and INab708 during the incubation, IL-8 levels were significantly attenuated (P ⁇ 0.01), while there was no significant reduction in the presence of L2B23.
  • DNA sequences encoding human C5a was obtained by reverse transcriptase- polymerase chain reaction (RT-PCR) using RNA isolated from peripheral blood leukocytes.
  • C5a mutants were generated using PCR methods by introducing the GCT (alanine) into the mutation site.
  • the C5a DNA was then ligated with pET-32a (Novagen, Gibbstown, NJ), and the ligation mixture was used to transform JM109-competent cells.
  • the expression plasmids were transformed into BL21 using a standard calcium chloride method. A single colony from a Luria-Bertani broth (LB) plate was picked up, inoculated into LB medium with ampicillin, and incubated at 37°C overnight.
  • LB Luria-Bertani broth
  • the culture was transferred to 2 L of LB medium and incubated at 37°C until the mid-exponential phase (A600 ⁇ 0.6), and then isopropyl- ?-D- thiogalactopyranoside (IPTG) was added to a final concentration of 0.1 mM.
  • IPTG isopropyl- ?-D- thiogalactopyranoside
  • the cells were allowed to continue to grow at 30°C overnight and harvested by spinning the culture at 7,000 rpm, 4°C, for 15 min. After washing with phosphate-buffered saline (PBS; 10 mM PB, 150 mM NaCl [pH 7.4]) once, the bacteria pellet was resuspended in PBS and sonicated on ice.
  • PBS phosphate-buffered saline
  • the soluble fraction was separated from insoluble pellet.
  • the supernatant of cell lysate was loaded on a nickel-chelated affinity column preequilibrated with PBS. Then the column was washed with 50 mM imidazole and 200 mM imidazole in PBS, respectively. Finally, the bound proteins were eluted by 500 mM imidazole, dialyzed against PBS overnight, and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
  • Monoclonal antibodies were made using hybridoma methods. Immunization and production of MAbs were carried out using standard protocols. Five 4-week-old female BALB/c mice were subcutaneously immunized with 100 ⁇ of purified recombinant C5a in complete Freund's adjuvant per animal. The animals were boosted twice at 4- week intervals using 100 ⁇ g of antigen in incomplete Freund's adjuvant. Three days after the final booster, mice were sacrificed, and its splenocytes were fused with NS-1 at a 5:1 ratio, and 200 ⁇ ⁇ of cells was plated in each well on five 96-well plates.
  • Hybrids were selected in a Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 20% fetal calf serum and 5 x 10 "3 M hypoxanthine, 2 * 10 "5 M aminopterin, and 8 x 10 "4 M thymidine (HAT).
  • DMEM Dulbecco's Modified Eagle's Medium
  • cell clones secreting antibodies against human C5a were screened by enzyme-linked immunosorbent assay (ELISA). Briefly, a 96-well plate was coated with 2 /zg/mL recombinant human C5a at 4°C overnight. After being blocked with 5% nonfat milk in PBS at 37°C for 1 h, 50 ⁇ ⁇ of culture media of the growing clones were added to each well and incubated at 37°C for 1 h, followed by 100 /zL of goat anti-mouse antibody labeled with horseradish peroxidase (HRP) for 1 h.
  • HRP horseradish peroxidase
  • the peroxidase reaction was developed with color development solution containing 5.5 mM o-phenylene-diamine hydrochloride (OPD) and 8.5 mM H 2 0 2 .
  • OPD o-phenylene-diamine hydrochloride
  • the light absorbance was measured at 492 nm with an ELISA reader (Anthos, Wals/Salzburg, Austria).
  • a binding Elisa was carried out to determine the binding activities of INab308 and INab708 to human C5a and C5a mutants.
  • C5a mutants are produced by replacing the correspondent amino acid with alanine by introduction of GCT into the mutation site from the cDNA level. These C5a mutants include site mutation on 24, 29, 30, 31, 32, 35, 36, 37, 30/37 double mutation, 40, 53, 64, 65, 66, 68, 64/68, 66/68, 69, 70, and C-del (12 amino acids were deleted from C5a C terminus).
  • Human C5a (Sigma C5788), recombinant C5a, and C5a mutants (2 ⁇ ug/mL) were coated on 96-well EIA plate (Costar 9018) at 4°C overnight. After being blocked with 5% nonfat milk in PBS at 37°C for 1 h, 0.08, 0.4, 2 ⁇ g/ml of anti-C5a antibodies (INab308 and INab708) prepared with dilution buffer were added to each well and incubated at 37°C for 1 h, followed by 100 ⁇ , of goat anti-mouse antibody labeled with horseradish peroxidase (HRP) for 1 h.
  • HRP horseradish peroxidase
  • the peroxidase reaction was developed with color development solution containing 5.5 mM o-phenylene-diamine hydrochloride (OPD) and 8.5 mM H 2 0 2 .
  • OPD o-phenylene-diamine hydrochloride
  • the light absorbance was measured at 492 nm with an ELISA reader (Anthos, Wals/Salzburg, Austria).
  • the OD value for recombinant C5a was set as 100% binding activity.
  • the binding capability of C5a mutants is calculated by ODc 5a mutam/ODcsa-
  • sheep red blood cells were prepared from fresh sheep whole blood by centrifugation, and then were sensitized with anti-sRBC.
  • Plasma samples from healthy volunteers were serially diluted and incubated with sensitized sRBC.
  • the unlysed cells were spun down, and the supematants were read at 542 nm on a plate reader.
  • equal volumes of anti-C5a antibody and plasma were pre-incubated for 1 hour prior to the addition of sensitized sRBC.
  • IL-8 Production in the whole blood model of E. coli infection To assess the efficacy of anti-C5a antibodies in the setting close to clinical sepsis, 250 ⁇ of whole blood from healthy volunteers were spiked with anti-C5a antibodies, and 250 ⁇ of E. coli diluted in saline buffer with a concentration of 1 x 10 7 /ml were then added. After 4-hour incubation at 37°C, the supernatants were spun down and collected for ELISA analysis for IL-8. IL-8 levels in the supernatants were analyzed by IL-8 ELISA kit (BioLegend, USA).
  • the spatial epitopes containing peptide C5a 28-40 (VN DETCEQRAAR, SEQ ID NO: 67) and C5a peptide 65- 70 (ISHKDM, SEQ ID NO: 68) can be viewed as random coils.
  • the two peptides are linked by a flexible peptide linker, GGGGS (SEQ ED NO: 69)
  • the spatial epitopes is reconstructed resembling the parent antigen conformation, as the weak hydrophobic interaction from the two peptides ensures a pocket-shape conformation.
  • a 96-well ELISA plate is coated with 1-2 ⁇ ug/mL synthetic peptides with the conformational epitope at 4°C overnight. After being blocked with 5% nonfat milk in PBS at 37°C for 1 h, 50 iL of culture media of the hybridoma growing clones are added to each well and incubated at 37°C for 1 h, followed by 100 /zL of goat anti-mouse antibody labeled with horseradish peroxidase (HRP) for 1 h. The peroxidase reaction is developed with color development solution containing 5.5 mM o-phenylene-diamine hydrochloride (OPD) and 8.5 mM H 2 0 2 . The light absorbance is measured at 492 nm with an ELISA reader.
  • HRP horseradish peroxidase
  • C5a mutants include site mutations on 24, 29, 30, 31, 32, 35, 36, 37, 30/37 double mutation, 40, 53, 64, 65, 66, 68, 64/68, 66/68, 69, 70, and C-del (12 amino acids were deleted from the C-terminus of C5a).
  • the C5a mutants were tested for their bioactivity to induce lysozyme release from human whole blood cells (Fig. 1).
  • C5a site mutation resulting in more than 50% bioactivity loss in comparison to human C5a was considered as a critical site for C5a biological function.
  • amino acid residues 24, 29, 31, 37, 68, and 69 were identified as sites critical for function (Fig. 1).
  • the regions identified for both antibodies cover four amino acid residues (31 , 37, 68, and 69) that were identified as sites critical for C5a function in section 2.1 above.
  • the total hemolytic complement titer (CH50) is a conventional method for determination of the activation of classical complement pathway (see section 1.6).
  • Monoclonal antibodies to C5a (INab708, INab308, and F20) were pre-incubated with human plasma at a concentration of approx. 5 ⁇ , and then the CH50 assay was performed.
  • F20 strongly inhibits CH50 activity, while INab708 and INab308 have no influence (Fig. 4).
  • E. co/7-induced IL-8 production in whole blood was determined.
  • This assay can be regarded as a model of E. coli infection (see also section 1.7).
  • Comparative antibodies 8g8, MAb 137-26, A 1876, G57, F20, L2B23, and G13 which do not bind simultaneously to both amino sequences of the conformational epitope identified in the present invention, i.e. amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3.
  • Comparative antibodies 8g8, MAb 137-26, F20, G57, L2B23, and G13 bind to only one of these two amino acid sequences (8g8, MAb 137-26, F20, G57, and G13) or to a different amino acid sequence (L2B23).
  • the target epitope of Abl 1876 is not known.
  • Monoclonal antibodies to human C5a were generated using classical hybridoma technology. Mabs' binding sites to human C5a were determined by alanine screening method. Mabs' blocking activities were quantitated by inhibition of C5a-induced lysozyme releases from human whole blood cells. Antibody Binding sites Affinity Ratio of Ab to Blocking
  • the present invention provides for the first time antibodies that exhibit an extremely high blocking activity, even when used just in stoichiometric amounts.
  • amino acid sequences of the complementarity determining regions of the heavy and light chains of antibodies INab308 and INab708 are listed below in Table 4.
  • Heavy Chain Heavy Chain:
  • CDR1 CKASGYSFTTFWMD
  • CDR1 CKATGNTFSGYWIE
  • FR2 WVKQRPGQGLEWIGR FR2: WVKQRPGHGLEWIGE
  • CDR3 CARGNDGYYGFAY
  • CDR3 CTRRGLYDGSSYFAY
  • DrVLTQSPASLAVSLGQRATIS FR1 DrVLTQSPASLAVSLGQRATIS (SEQ ID NO: 55) (SEQ ID NO: 63)
  • FR2 WYQQKPGQPPKLL FR2: WYQQKPGQPPKLL
  • CDR3 CQQSNEDPYT
  • CDR3 CQQNNEDPLT
  • FR4 FGGGTKLEIK FR4: FGAGTLLELK (SEQ ID NO: 58) (SEQ ID NO: 66)
  • Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 160(5): 1867-1875.
  • Damschroder MM Widjaja L, Gill PS, Krasnoperov V, Jiang W, Dall'Acqua WF, and Wu H.
  • SEQ ID NO: 18 Consensus sequence of C5a in the region of amino acids 30-38

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention concerne des fractions de liaison qui se lient spécifiquement à un épitope conformationnel de C5a, en particulier C5a humain. Les fractions de liaison préférées sont des anticorps anti-C5a qui se lient à cet épitope conformationnel. Les fractions de liaison décrites présentement sont utiles comme agents actifs dans des compositions pharmaceutiques pour le traitement et la prévention de diverses maladies aigues et chroniques, en particulier des maladies inflammatoires aigues telles que le syndrome de réponse inflammatoire systémique (SIRS) et différents degrés de sepsie comprenant la sepsie, la sepsie grave et le choc septique.
EP10782561.4A 2009-11-26 2010-11-26 Groupes caractéristiques à liaison anti-c5a avec une activité à blocage élevé Active EP2504362B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RS20170025A RS55571B1 (sr) 2009-11-26 2010-11-26 Anti-c5a vezujuće grupe sa visokom blokirajućom aktivnosti
DK16199344.9T DK3181582T3 (da) 2009-11-26 2010-11-26 Anti-c5a-bindingsdele med høj blokeringsaktivitet
EP20153768.5A EP3670532A1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage
PL16199344T PL3181582T3 (pl) 2009-11-26 2010-11-26 Grupy wiążące białko C5A o wysokiej aktywności blokującej
EP10782561.4A EP2504362B1 (fr) 2009-11-26 2010-11-26 Groupes caractéristiques à liaison anti-c5a avec une activité à blocage élevé
SI201031368A SI2504362T1 (sl) 2009-11-26 2010-11-26 Anti-C5A vezavni deli z visoko dejavnostjo blokiranja
EP16199344.9A EP3181582B1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage
PL10782561T PL2504362T3 (pl) 2009-11-26 2010-11-26 Grupy wiążące białko C5A o wysokiej aktywności blokującej
HRP20170041TT HRP20170041T1 (hr) 2009-11-26 2017-01-11 Anti-c5a vezujuće grupe s visokom blokirajućom aktivnošću
CY20171100048T CY1118463T1 (el) 2009-11-26 2017-01-12 Αντι-c5a συνδετικα μορια με υψηλου βαθμου δραστικοτητα αποκλεισμου
SM201700054T SMT201700054B (it) 2009-11-26 2017-01-24 Porzioni leganti anti-c5a con elevata attività bloccante
CY20201100151T CY1122674T1 (el) 2009-11-26 2020-02-19 Αντι-c5α συνδετiκα μορια με υψηλου βαθμου δραστiκοτητα αποκλεισμου

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26469609P 2009-11-26 2009-11-26
EP09014745A EP2327725A1 (fr) 2009-11-26 2009-11-26 Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
PCT/EP2010/007197 WO2011063980A1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a à activité bloquante élevée
EP10782561.4A EP2504362B1 (fr) 2009-11-26 2010-11-26 Groupes caractéristiques à liaison anti-c5a avec une activité à blocage élevé

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP20153768.5A Division EP3670532A1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage
EP16199344.9A Division EP3181582B1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage

Publications (2)

Publication Number Publication Date
EP2504362A1 true EP2504362A1 (fr) 2012-10-03
EP2504362B1 EP2504362B1 (fr) 2016-11-23

Family

ID=41683202

Family Applications (4)

Application Number Title Priority Date Filing Date
EP09014745A Withdrawn EP2327725A1 (fr) 2009-11-26 2009-11-26 Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
EP16199344.9A Active EP3181582B1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage
EP20153768.5A Withdrawn EP3670532A1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage
EP10782561.4A Active EP2504362B1 (fr) 2009-11-26 2010-11-26 Groupes caractéristiques à liaison anti-c5a avec une activité à blocage élevé

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP09014745A Withdrawn EP2327725A1 (fr) 2009-11-26 2009-11-26 Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
EP16199344.9A Active EP3181582B1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage
EP20153768.5A Withdrawn EP3670532A1 (fr) 2009-11-26 2010-11-26 Fractions de liaison anti-c5a présentant une forte activité de blocage

Country Status (26)

Country Link
US (4) US8802096B2 (fr)
EP (4) EP2327725A1 (fr)
JP (4) JP6104605B2 (fr)
KR (3) KR20180034690A (fr)
CN (2) CN105037541A (fr)
AU (1) AU2010324141B2 (fr)
BR (1) BR112012012514B1 (fr)
CA (1) CA2780520C (fr)
CL (1) CL2012001304A1 (fr)
CY (2) CY1118463T1 (fr)
DK (2) DK3181582T3 (fr)
EA (1) EA022759B1 (fr)
ES (2) ES2613352T3 (fr)
HR (2) HRP20170041T1 (fr)
HU (2) HUE032543T2 (fr)
IL (1) IL219911A (fr)
LT (2) LT3181582T (fr)
MX (1) MX2012006060A (fr)
NZ (1) NZ600348A (fr)
PE (1) PE20130314A1 (fr)
PL (2) PL2504362T3 (fr)
PT (2) PT2504362T (fr)
RS (2) RS55571B1 (fr)
SI (2) SI2504362T1 (fr)
SM (1) SMT201700054B (fr)
WO (1) WO2011063980A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
US8703129B2 (en) 2008-09-07 2014-04-22 GlycoNex, Inc. Antibodies against extended type 1 chain antigens, derivatives thereof and use
EP2327725A1 (fr) 2009-11-26 2011-06-01 InflaRx GmbH Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
EP2647706B1 (fr) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PL2817329T3 (pl) * 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polipeptydy wiążące z c5 ludzkiego dopełniacza
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
MY176200A (en) 2013-08-28 2020-07-24 Affibody Ab Binding polypeptides having a mutated scaffold
KR102446636B1 (ko) 2013-08-28 2022-09-23 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 안정한 폴리펩티드
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MX2016011862A (es) * 2014-03-20 2016-12-05 Inflarx Gmbh Inhibidores de c5a para el tratamiento de la neumonia viral.
WO2016040294A2 (fr) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-cd38
NZ732753A (en) 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
ES2890783T3 (es) 2015-06-22 2022-01-24 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
WO2017196960A1 (fr) * 2016-05-10 2017-11-16 Annexon, Inc. Anticorps anti-facteur du complément c4/c4b et utilisations de ceux-ci
UA124734C2 (uk) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Антитіло проти с5 і його застосування
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
CA3055541A1 (fr) * 2017-03-06 2018-09-13 The Trustees Of The University Of Pennsylvania Anticorps anti-c5 et leurs utilisations
EP3600421A4 (fr) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania Anticorps anti-c5a et utilisations de ceux-ci
EP4272821A3 (fr) 2017-04-03 2024-01-03 InflaRx GmbH Traitement de maladies inflammatoires au moyen d'inhibiteurs de l'activité c5a
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
KR20200020727A (ko) 2017-06-23 2020-02-26 인플라알엑스 게엠베하 C5a 활성의 억제제를 사용한 염증 질병의 치료
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
EP3724226A1 (fr) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Associations d'anticorps anti-c5 et utilisations associées
EP3586865A1 (fr) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Liants d'anaphylatoxine de complément et leur utilisation dans le traitement d'un sujet présentant une plaie oculaire et/ou une fibrose
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3846850A4 (fr) 2018-09-06 2022-06-15 The Trustees of the University of Pennsylvania Anticorps humanisés anti-c5 et leurs utilisations
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
CN118791602A (zh) * 2020-06-24 2024-10-18 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
MX2023008302A (es) 2021-01-13 2023-09-25 Visterra Inc Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos.
WO2023050233A1 (fr) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Anticorps anti-c5a humanisés et leurs utilisations
CN116670288A (zh) * 2021-12-22 2023-08-29 舒泰神（北京）生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用
WO2023186054A1 (fr) * 2022-04-02 2023-10-05 舒泰神（北京）生物制药股份有限公司 Anticorps reconnaissant de manière spécifique c5a et utilisation associée

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP3372243A1 (fr) * 2001-08-17 2018-09-12 Genentech, Inc. Inhibiteurs de chemin d'accès complémentaires liant c5 et c5a sans empêcher la formation de c5b
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
EP2327725A1 (fr) * 2009-11-26 2011-06-01 InflaRx GmbH Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Christian Klein ET AL: "Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties", mAbs, vol. 5, no. 1, 1 January 2013 (2013-01-01) , pages 22-33, XP055117097, ISSN: 1942-0862, DOI: 10.4161/mabs.22771 *
See also references of WO2011063980A1 *

Also Published As

Publication number Publication date
US20170002067A1 (en) 2017-01-05
JP2016074721A (ja) 2016-05-12
CA2780520C (fr) 2021-11-23
HRP20170041T1 (hr) 2017-03-10
PT3181582T (pt) 2020-03-03
EA022759B1 (ru) 2016-02-29
HUE049376T2 (hu) 2020-09-28
DK3181582T3 (da) 2020-02-24
EP2327725A1 (fr) 2011-06-01
ES2773725T3 (es) 2020-07-14
KR20120089346A (ko) 2012-08-09
CY1122674T1 (el) 2021-03-12
RS59955B1 (sr) 2020-03-31
HUE032543T2 (en) 2017-10-30
SI2504362T1 (sl) 2017-03-31
US9073983B2 (en) 2015-07-07
JP2019163266A (ja) 2019-09-26
KR102112969B1 (ko) 2020-05-19
HRP20200241T1 (hr) 2020-06-12
KR101844611B1 (ko) 2018-04-02
AU2010324141A1 (en) 2012-06-21
CL2012001304A1 (es) 2012-08-03
BR112012012514A2 (pt) 2020-07-28
BR112012012514B1 (pt) 2022-10-04
US10774136B2 (en) 2020-09-15
US8802096B2 (en) 2014-08-12
US20140314772A1 (en) 2014-10-23
US9458233B2 (en) 2016-10-04
JP2013512209A (ja) 2013-04-11
JP2018080170A (ja) 2018-05-24
LT2504362T (lt) 2017-02-10
MX2012006060A (es) 2012-06-19
LT3181582T (lt) 2020-02-25
US20150266949A1 (en) 2015-09-24
JP6591272B2 (ja) 2019-10-16
EP3181582A1 (fr) 2017-06-21
PL2504362T3 (pl) 2017-08-31
ES2613352T3 (es) 2017-05-24
CY1118463T1 (el) 2017-07-12
JP6104605B2 (ja) 2017-03-29
US20120231008A1 (en) 2012-09-13
KR20180034690A (ko) 2018-04-04
IL219911A (en) 2017-03-30
WO2011063980A1 (fr) 2011-06-03
RS55571B1 (sr) 2017-05-31
SMT201700054B (it) 2017-03-08
SI3181582T1 (sl) 2020-03-31
CN102741283B (zh) 2015-07-15
EP2504362B1 (fr) 2016-11-23
AU2010324141B2 (en) 2014-04-10
CN102741283A (zh) 2012-10-17
KR20190039357A (ko) 2019-04-10
DK2504362T3 (en) 2017-01-30
EP3670532A1 (fr) 2020-06-24
PL3181582T3 (pl) 2020-06-01
PE20130314A1 (es) 2013-04-03
NZ600348A (en) 2014-01-31
EP3181582B1 (fr) 2020-01-29
EA201200795A1 (ru) 2013-04-30
CA2780520A1 (fr) 2011-06-03
CN105037541A (zh) 2015-11-11
PT2504362T (pt) 2017-01-18
IL219911A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
US10774136B2 (en) Anti-C5a binding moieties with high blocking activity
KR102557216B1 (ko) 그렘린-1 결정 구조 및 억제 항체
NZ739871A (en) Tissue factor pathway inhibitor antibodies and uses thereof
TW201143789A (en) Antigen binding proteins
WO2016039402A1 (fr) Anticorps monoclonal humanisé destiné à inhiber l'activité de l'enzyme lipase endothéliale vasculaire
CN112839957A (zh) Il-36抗体及其用途
JP2019534850A (ja) 抗ｇｍ−ｃｓｆ抗体およびその使用
GUO et al. Patent 2780520 Summary
RU2574786C2 (ru) Антикиновые антитела, которые связываются с несколькими сс-хемокинами

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130917

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160812

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 847828

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010038287

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20170041

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2504362

Country of ref document: PT

Date of ref document: 20170118

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20170110

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170124

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI AND CIE SA, CH

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20170041

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E013223

Country of ref document: EE

Effective date: 20170112

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20161123

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2613352

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170524

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 23134

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010038287

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E032543

Country of ref document: HU

26N No opposition filed

Effective date: 20170824

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170041

Country of ref document: HR

Payment date: 20181114

Year of fee payment: 9

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 847828

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161123

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010038287

Country of ref document: DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170041

Country of ref document: HR

Payment date: 20191119

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170041

Country of ref document: HR

Payment date: 20201117

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170041

Country of ref document: HR

Payment date: 20211119

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170041

Country of ref document: HR

Payment date: 20221116

Year of fee payment: 13

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170041

Country of ref document: HR

Payment date: 20231114

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231122

Year of fee payment: 14

Ref country code: LU

Payment date: 20231120

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231116

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231120

Year of fee payment: 14

Ref country code: GB

Payment date: 20231123

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20231121

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231215

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20231123

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231116

Year of fee payment: 14

Ref country code: SM

Payment date: 20231117

Year of fee payment: 14

Ref country code: SI

Payment date: 20231114

Year of fee payment: 14

Ref country code: SE

Payment date: 20231123

Year of fee payment: 14

Ref country code: RS

Payment date: 20231124

Year of fee payment: 14

Ref country code: RO

Payment date: 20231117

Year of fee payment: 14

Ref country code: PT

Payment date: 20231110

Year of fee payment: 14

Ref country code: NO

Payment date: 20231121

Year of fee payment: 14

Ref country code: MT

Payment date: 20231122

Year of fee payment: 14

Ref country code: LV

Payment date: 20231117

Year of fee payment: 14

Ref country code: LT

Payment date: 20231109

Year of fee payment: 14

Ref country code: IT

Payment date: 20231130

Year of fee payment: 14

Ref country code: IE

Payment date: 20231117

Year of fee payment: 14

Ref country code: HU

Payment date: 20231121

Year of fee payment: 14

Ref country code: HR

Payment date: 20231114

Year of fee payment: 14

Ref country code: FR

Payment date: 20231124

Year of fee payment: 14

Ref country code: FI

Payment date: 20231120

Year of fee payment: 14

Ref country code: EE

Payment date: 20231120

Year of fee payment: 14

Ref country code: DK

Payment date: 20231122

Year of fee payment: 14

Ref country code: DE

Payment date: 20231123

Year of fee payment: 14

Ref country code: CZ

Payment date: 20231110

Year of fee payment: 14

Ref country code: CH

Payment date: 20231201

Year of fee payment: 14

Ref country code: BG

Payment date: 20231117

Year of fee payment: 14

Ref country code: AT

Payment date: 20231117

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231120

Year of fee payment: 14

Ref country code: BE

Payment date: 20231121

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20231110

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20231124

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20231128

Year of fee payment: 14